BACKGROUND: Cognitive deficits are a core feature of early stages in schizophrenia. However, the extent to which antipsychotic (AP) have a deleterious effect on cognitive performance remains under debate. We aim to investigate whether anticholinergic loadings and dose of AP drugs in first episode of psychosis (FEP) in advanced phase of remission are associated with cognitive impairment and the differences between premorbid intellectual quotient (IQ) subgroups. METHODS: Two hundred and sixty-six patients participated. The primary outcomes were cognitive dimensions, dopaminergic/anticholinergic load of AP [in chlorpromazine equivalents (Eq-CPZ) and the Anticholinergic Risk Scale (ARS), respectively]. RESULTS: Impairments in processing speed, verbal memory and global cognition were significantly associated with high Eq-CPZ and verbal impairment with high ARS score. Moreover, this effect was higher in the low IQ subgroup. CONCLUSIONS: Clinicians should be aware of the potential cognitive impairment associated with AP in advanced remission FEP, particularly in lower premorbid IQ patients.
BACKGROUND:Cognitive deficits are a core feature of early stages in schizophrenia. However, the extent to which antipsychotic (AP) have a deleterious effect on cognitive performance remains under debate. We aim to investigate whether anticholinergic loadings and dose of AP drugs in first episode of psychosis (FEP) in advanced phase of remission are associated with cognitive impairment and the differences between premorbid intellectual quotient (IQ) subgroups. METHODS: Two hundred and sixty-six patients participated. The primary outcomes were cognitive dimensions, dopaminergic/anticholinergic load of AP [in chlorpromazine equivalents (Eq-CPZ) and the Anticholinergic Risk Scale (ARS), respectively]. RESULTS: Impairments in processing speed, verbal memory and global cognition were significantly associated with high Eq-CPZ and verbal impairment with high ARS score. Moreover, this effect was higher in the low IQ subgroup. CONCLUSIONS: Clinicians should be aware of the potential cognitive impairment associated with AP in advanced remission FEP, particularly in lower premorbid IQ patients.
Entities:
Keywords:
Anticholinergic; antipsychotics; cognition; first episode psychosis; premorbid intellectual quotient.
Authors: A Koyanagi; B Stubbs; E Lara; N Veronese; D Vancampfort; L Smith; J M Haro; H Oh; J E DeVylder Journal: Epidemiol Psychiatr Sci Date: 2018-12-26 Impact factor: 6.892
Authors: Paul Klauser; Vanessa L Cropley; Philipp S Baumann; Jinglei Lv; Pascal Steullet; Daniella Dwir; Yasser Alemán-Gómez; Meritxell Bach Cuadra; Michel Cuenod; Kim Q Do; Philippe Conus; Christos Pantelis; Alex Fornito; Tamsyn E Van Rheenen; Andrew Zalesky Journal: Schizophr Bull Open Date: 2021-07-17
Authors: Philip D Harvey; Marta Bosia; Roberto Cavallaro; Oliver D Howes; René S Kahn; Stefan Leucht; Daniel R Müller; Rafael Penadés; Antonio Vita Journal: Schizophr Res Cogn Date: 2022-03-22
Authors: Tommy Aa Broeders; Alex A Bhogal; Lisan M Morsinkhof; Menno M Schoonheim; Christian H Röder; Mirte Edens; Dennis Wj Klomp; Jannie P Wijnen; Christiaan H Vinkers Journal: J Psychopharmacol Date: 2022-03-04 Impact factor: 4.562
Authors: Francesco Dal Santo; Leticia González-Blanco; Leticia García-Álvarez; Lorena de la Fuente-Tomás; Ángela Velasco; Clara María Álvarez-Vázquez; Clara Martínez-Cao; Pilar A Sáiz; María Paz García-Portilla; Julio Bobes Journal: Sci Rep Date: 2020-09-29 Impact factor: 4.379